Introduction
Louse-borne relapsing fever (LBRF) is an acute febrile infection that is typically characterized by one to three fairly regular waves of bacteremia [1,2]. It is caused by Borrelia recurrentis, a motile spirochete that measures 5 to 40 μm in length. The microorganism is transmitted from person to person by the human body louse (Pediculus humanus humanus). Disruptions in sanitation during wartime and mass migrations of people provide conditions that favor the propagation of body lice and thus the occurrence of outbreaks of the disease [1,3]. LBRF is endemic in East Africa (e.g., Ethiopia, Eritrea, Somalia, and Sudan) with the highest number of cases observed in Ethiopia, where it is the seventh most common cause of hospital admission and the fifth most common cause of death [4,5]. We report here the first case of imported LBRF observed in Lombardy (northern Italy) in a Somali refugee.
Case Presentation
On 13 September 2015, a 22-year-old refugee from Somalia presented to the Emergency Department (ED) of Luigi Sacco Hospital complaining of high fever, headache, chills, nausea, vomiting, and diffuse myalgias. He had arrived in Italy six days earlier after stopovers in Sudan (three weeks) and Libya (two months) on the way to our country. On the ninth of September he reported the onset of fever. On presentation, the patient was mildly febrile (37.3°C), tachypneic (respiratory rate 32 breaths per minute), hypotensive (90/60 mmHg), and showed bilateral hyperemic conjunctivae. The remainder of the physical examination was unremarkable. Routine blood tests demonstrated severe thrombocytopenia (23 x 109/L), a normal leukocyte count with lymphocytopenia (7.3 x 109/L; 6%), a C-reactive protein concentration of 440.9 mg/L (normal < 3 mg/L) and high venous lactate levels (3.9 mmol/L). Chest X-ray and abdominal ultrasound examination were reportedly normal. Thick and thin blood films were negative for malaria parasites, along with a rapid diagnostic antigen test. A second febrile peak (38.5°C) while the patient was in the ED and before inception of empirical antibiotic therapy with piperacillin/tazobactam (4.5 g ev) was remarkable due to the presence of a large number of extracellular spirochetes detected on blood film (Fig 1).
Serological screening tests for human immunodeficiency virus (HIV) and syphilis were negative. A western immunoblot for Borrelia species was positive for both IgG and IgM (p41, p39, OspC). The patient was admitted to our infectious diseases ward with a tentative diagnosis of borreliosis. No body lice were detected from his clothing, but it should be noted that they were changed upon arrival in Italy. He was also negative for the presence of head lice. Antibiotic therapy was switched to 100 mg of doxycycline twice per day and was stopped after three days. Jarisch-Herxheimer reaction did not occur. The patient made a full recovery, with platelet counts returning to normal values by the seventh day, and was discharged without consequences.
Identification of Bacterial Agent
Broad range 16S rRNA polymerase chain reaction (PCR) was performed on DNA extracted from the blood drawn before administration of antimicrobial therapy. A real-time PCR based on rrs (16S rRNA) gene and aimed to amplify all species of Borrelia [6] was also positive. In order to identify borrelial species causing the fever in this patient, we amplified a 344 bps portion of a flaB (flagellin) gene [7] and a 1395 bps portion of rrs using Borrelia genus-specific primers. Sequenced amplicons of both genes showed 100% identity (297/297 for flaB and 1269/1269 for rrs) with the B. recurrentis strain A1 CP000993 (Fig 2).
Case Discussion
We report here the first case of imported LBRF diagnosed in northern Italy in a Somali refugee that was observed almost concomitantly with similar cases in East African refugees in the Netherlands, Switzerland [8,9], southern and northern Italy [10,11], and Germany [12] in a very limited time span.
Louse-borne relapsing fever is caused by the spirochete B. recurrentis with humans being the only reservoir [1]. It is usually transmitted by the rupture of a body louse with subsequent auto-inoculation caused by scratching of the skin due to presence of Borrelia in the hemolymph of the arthropod. The recent demonstration of prolonged excretion of the bacterium in the feces of the louse provides an alternative explanation for a more efficient means of transmission [2,13]. Although a study showed that B. recurrentis can be frequently identified in head lice (Pediculus humanus capitis) of patients with LBRF, the possible role of the latter in human transmission of the disease still remains to be demonstrated [14]. During World Wars I and II, epidemics of relapsing fever affected millions of people worldwide. Subsequently, the disease disappeared from western countries, while it still remains a fairly common and important disorder in Eastern Africa (especially in Ethiopia, Eritrea, Somalia, and Sudan) [4,5,15,16].
The ongoing “humanitarian crisis” with thousands of refugees and migrants daily arriving to the European Union after perilous journeys in crowded and poor hygienic conditions is a definite risk factor for possible explosive outbreaks of arthropod-borne diseases [3,17,18]. Language barriers, which hamper the acquisition of accurate clinical and travel history, coupled with unfamiliarity with these disorders are a challenge for western physicians. As in the case of this patient, all other individuals with LBRF identified in the European Union had travelled from the Horn of Africa through Sudan and Libya before arriving in Europe. These cases altogether suggest that B. recurrentis is currently circulating among East African refugees, most of whom first arrive in Italy as “boat people” after having waited for long periods of time in Libya. Since the incubation period of LBRF is relatively short (mean: 7 days, range: 2–18 days), we may hypothesize the existence of an “epidemic chain” that probably begins in Somalia and is then fueled by the “relapsing nature” of the microorganism, together with high rates of body louse infestation, crowding, and poor hygienic conditions that are well known to affect migrants and refugees in their long journeys to Europe. It is also likely that a new focal point of infection might have been established in Libya. The disease is characterized by signs and symptoms that are not specific and may mimic a sepsis-like syndrome or other febrile infectious diseases that are associated with thrombocytopenia (e.g., malaria, leptospirosis, rickettsiosis, meningococcal sepsis, or viral hemorrhagic fevers). Low platelet counts were indeed described in 11 of the 12 patients whose published cases were detailed [8–11], including the present one. The diagnosis of borreliosis is easily accomplished by the observation of spirochetes in the peripheral blood smear collected during febrile episodes due to the high bacterial load. However, we believe that these pathogens may go unnoticed to the inexperienced or unaware observer, or when blood samples are taken in the afebrile period or after starting antibiotic treatment. Finally, the identification of the microorganism at the species level should be actively pursued, because several tick-borne borreliae (e.g., Borrelia duttonii, Borrelia hispanica, and Borrelia crocidurae) have been documented in Africa [15,16]. Moreover, several species that are pathogenic for humans, but not yet completely characterized, were recently reported from Northern and Eastern Africa [19,20].
This is not a purely epidemiologic or microbiologic undertaking, but is of paramount therapeutic relevance because LBRF requires a single-dose antibiotic treatment, as opposed to a seven- to ten-day schedule for the tick-borne relapsing fevers. However, the correct identification of Borrelia at the species level is a task that can be accomplished only by reference laboratories using molecular tools and sequencing.
Conclusion and Recommendation
Physicians should be aware of the possibility that initial therapy may precipitate a Jarisch-Herxheimer reaction, which was actually observed in 15 out of the 27 patients described up to now in Europe and probably caused one death [8–12]. Prompt recognition of LBRF among refugees from East Africa and appropriate antibiotic treatment are essential to avoid re-emergence of louse-borne infections in Europe and to reduce death from this disease, which can be as high as 20%–40% among malnourished and frail individuals. In all diagnosed cases of LBRF, clothes should be replaced or washed at high temperatures (>60°C). Management of body lice includes both bathing with soap and water and treatment with topical or systemic pediculicides. Close contacts of affected patients should be investigated for the presence of body lice and eventually deloused and/or treated with a single-dose prophylaxis of doxycycline.
Key Learning Points
Louse-borne relapsing fever is increasingly observed among asylum seekers from the Horn of Africa arriving in Europe after prolonged stay in refugee camps in Libya.
A sepsis-like picture associated with thrombocytopenia should raise the clinical suspicion of this disease.
High bacterial load observed during febrile episodes makes the diagnosis straightforward when blood smears are examined, but the diagnosis may be missed by unskilled observers or when blood is collected after antibiotic treatment.
A Jarisch-Herxheimer reaction might be precipitated by antibiotic treatment.
Prompt recognition of this disease among refugees coming from East Africa and appropriate delousing are essential to avoid re-emergence of LBRF in Europe.
Acknowledgments
We thank Mrs. Tiziana Formenti, Bianca Ghisi, and Letizia Oreni for helpful technical assistance in the preparation of images.
Funding Statement
The authors received no specific funding for this work.
References
- 1.Raoult D, Roux V. The body louse as a vector of reemerging human diseases. Clin Infect Dis 1999;29:888–911. [DOI] [PubMed] [Google Scholar]
- 2.Badiaga S, Brouqui P. Human louse-transmitted infectious diseases. Clin Microbiol Infect 2012;18:332–7. 10.1111/j.1469-0691.2012.03778.x [DOI] [PubMed] [Google Scholar]
- 3.Brouqui P. Arthropod-borne diseases associated with political and social disorder. Annu Rev Entomol 2011;56:357–74. 10.1146/annurev-ento-120709-144739 [DOI] [PubMed] [Google Scholar]
- 4.Tewdros E, Getahun A, Fekadu B. Relapsing fever in Hossana, Ethiopia: a clinical and epidemiological study. Ethip J Health Sci 2002; 12:103–8. [Google Scholar]
- 5.Yimer M, Abera B, Mulu W, Bezabih B, Mohammed J. Prevalence and risk factors of louse-borne relapsing fever in high risk populations in Bahir Dar city Northwest, Ethiopia. BMC Research Notes 2014;7:615 10.1186/1756-0500-7-615 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Mediannikov O, Socolovschi C, Bassene H, Diatta G, Ratmanov P, Fenollar F, et al. Borrelia crocidurae infection in acutely febrile patients, Senegal. Emerg Infect Dis 2014;20:1335–8 10.3201/eid2008.130550 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Vial L1, Durand P, Arnathau C, Halos L, Diatta G, Trape JF, et al. Molecular divergences of the Ornithodoros sonrai soft tick species, a vector of human relapsing fever in West Africa. Microbes Infect 2006;8:2605–11. [DOI] [PubMed] [Google Scholar]
- 8.Wilting KR, Stienstra Y, Sinha B, Braks M, Cornish D, Grundmann H. Louse-borne relapsing fever (Borrelia recurrentis) in asylum seekers from Eritrea, the Netherlands, July 2015. Euro Surveill 2015; 20(30); pii = 21196. [DOI] [PubMed] [Google Scholar]
- 9.Goldenberger D, Claas GJ, Bloch-Infanger C, Breidthardt T, Suter B, Martinez M, et al. Louse-borne relapsing fever (Borrelia recurrentis) in an Eritrean refugee arriving in Switzerland, August 2015. Euro Surveill 2015;20(32):2–5. [PubMed] [Google Scholar]
- 10.Ciervo A, Mancini F, di Berenardo F, Giammanco A, Vitale G, Dones P, et al. Louse-borne relapsing fever in young migrants, Sicily, Italy, July-September 2015. Emerg Infect Dis 2016; 22:152–3. 10.3201/eid2201.151580 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R, Carosella S, et al. Louseborne relapsing fever among East African refugees, Italy, 2015. Emerg Infect Dis 2016; 22:298–301. 10.3201/eid2202.151768 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hoch M, Wieser A, Loscher T, Margos G, Purner F, Seilmaier M, et al. Louse-borne relapsing fever (Borrelia recurrentis) diagnosed in 15 refugees from northeast Africa: epidemiology and preventive control measures, Bavaria, Germany, July to October 2015. Euro Surveill 2015; 20(42); 10.2807/1560-7917.ES2015.20.42.30046 [DOI] [PubMed] [Google Scholar]
- 13.Houhamdi L, Raoult D. Excretion of living Borrelia recurrentis in feces of infected human body lice. J Infect Dis 2005;191:1898–1906. [DOI] [PubMed] [Google Scholar]
- 14.Boutellis A, Mediannikov O, Bilcha KD, Ali J, Campelo D, Barker SC, et al. Borrelia recurrentis in head lice, Ethiopia. Emerg Infect Dis 2013,19796–8. 10.3201/eid1905.121480 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Cutler SJ, Abdissa A, Trape JF. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol Infect 2009;15:400–6. 10.1111/j.1469-0691.2009.02819.x [DOI] [PubMed] [Google Scholar]
- 16.Elbir H, Raoult D, Drancourt M. Relapsing fever borreliae in Africa. Am J Trop Med Hyg 2013;89:288–92. 10.4269/ajtmh.12-0691 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Nicolai T, Fuchs O, von Mutius E. Caring for the wave of refugees in Munich. N Engl J Med 2015; 373: 1593–5. 10.1056/NEJMp1512139 [DOI] [PubMed] [Google Scholar]
- 18.Cutler S. Refugee crisis and re-emergence of forgotten infections in Europe. Clin Microbiol Infect 2016; 22:8–9. 10.1016/j.cmi.2015.10.018 [DOI] [PubMed] [Google Scholar]
- 19.Fotso Fotso A, Angelakis E, Mouffok N, Drancourt M, Raoult D. Blood-Borne Candidatus Borrelia algerica in a Patient with Prolonged Fever in Oran, Algeria. Am J Trop Med Hyg. 2015; 93:1070–3. 10.4269/ajtmh.15-0124 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kisinza WN, McCall PJ, Mitani H, Talbert A, Fukunaga M. A newly identified tick-borne Borrelia species and relapsing fever in Tanzania. Lancet 2003; 362:1283–1284. [DOI] [PubMed] [Google Scholar]